JP2020510611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510611A5 JP2020510611A5 JP2019524425A JP2019524425A JP2020510611A5 JP 2020510611 A5 JP2020510611 A5 JP 2020510611A5 JP 2019524425 A JP2019524425 A JP 2019524425A JP 2019524425 A JP2019524425 A JP 2019524425A JP 2020510611 A5 JP2020510611 A5 JP 2020510611A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- fam46a
- polypeptide
- polynucleotide
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 102100003999 TENT5A Human genes 0.000 claims 9
- 101710037956 TENT5A Proteins 0.000 claims 9
- 229920000023 polynucleotide Polymers 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 3
- 102000016267 Leptin Human genes 0.000 claims 3
- 108010092277 Leptin Proteins 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 229940039781 leptin Drugs 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 2
- 229960002695 Phenobarbital Drugs 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N 11,19,21-trihydroxy-22-[5-[5-(1-hydroxyethyl)-5-methyloxolan-2-yl]-5-methyloxolan-2-yl]-4,6,8,12,14,18,20-heptamethyl-9-oxodocosa-10,16-dienoic acid Chemical compound O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims 1
- 229940022659 Acetaminophen Drugs 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N Clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 229940119017 Cyclosporine Drugs 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229960000684 Cytarabine Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 229960002380 Dibutyl Phthalate Drugs 0.000 claims 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Diethyl maleate Chemical compound CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 claims 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N Dirurol Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005510 Diuron Substances 0.000 claims 1
- 229950005837 Entinostat Drugs 0.000 claims 1
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N Fipronil Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 claims 1
- 239000005899 Fipronil Substances 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 108020004388 MicroRNAs Proteins 0.000 claims 1
- DSRJIHMZAQEUJV-UHFFFAOYSA-N N,N'-bis(cyclohexylideneamino)oxamide Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 claims 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 229920001891 Small hairpin RNA Polymers 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 230000003356 anti-rheumatic Effects 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229920002847 antisense RNA Polymers 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229940013764 fipronil Drugs 0.000 claims 1
- 229960002163 hydrogen peroxide Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- BABMCXWQNSQAOC-UHFFFAOYSA-M methylmercury chloride Chemical compound C[Hg]Cl BABMCXWQNSQAOC-UHFFFAOYSA-M 0.000 claims 1
- 229920001239 microRNA Polymers 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000005445 natural product Substances 0.000 claims 1
- 229930014626 natural products Natural products 0.000 claims 1
- -1 nephazodone Chemical compound 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- SIDINRCMMRKXGQ-UHFFFAOYSA-N perfluoroundecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SIDINRCMMRKXGQ-UHFFFAOYSA-N 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Claims (14)
- FAM46Aの活性を低下させることができる作用物質を含む、体重維持の支援及び/又は肥満を治療若しくは予防するための組成物。
- 前記作用物質が、減量介入中又は減量介入後に対象に投与される、請求項1に記載の組成物。
- 前記作用物質が、対象のレプチンレベルを増大させる、請求項1又は2に記載の組成物。
- 前記作用物質が、対象のレプチンレベルを増大させる、請求項1〜3のいずれか一項に記載の組成物。
- 前記作用物質が、対象のFAM46Aレベルを減少させる、請求項1〜4のいずれか一項に記載の組成物。
- 前記作用物質が、アセトアミノフェン、抗リウマチ作用物質、ベンゾ(a)ピレン、カルバマゼピン、クロフィブラート、クプリゾン、シクロスポリン、シタラビン、ジブチルフタレート、ジエチルマレエート、ジエチルニトロサミン、ジウロン、エンチノスタット、フィプロニル、過酸化水素、イオノマイシン、レフルノミド、塩化メチル水銀、ネファゾドン、パーフルオロ−n−ウンデカン酸、フェノバルビタール、フェノバルビタール、ピリニクス酸、テトラクロロジベンゾジオキシン、テトラデカノイルホルボールアセテート、トレチノイン、トリコスタチンA、バルプロ酸、及びビンクロゾリンからなる群から選択される、請求項1〜5のいずれか一項に記載の組成物。
- 前記作用物質が、siRNA、shRNA、miRNA、アンチセンスRNA、ポリヌクレオチド、ポリペプチド、及び小分子からなる群から選択される、請求項1〜5のいずれか一項に記載の組成物。
- 対象の体重維持を支援すること、及び/又は肥満を治療又は予防することができる作用物質を同定する方法であって、
(a) FAM46Aポリペプチド又はポリヌクレオチドを含む調製物を、候補となる作用物質と接触させる工程と、
(b) 前記候補となる作用物質が、前記FAM46Aポリペプチド又はポリヌクレオチドの活性に影響を及ぼすかどうかを検出する工程と、を含む、方法。 - FAM46Aの活性を低下させる作用物質を同定する方法であって、
(a) FAM46Aポリペプチド又はポリヌクレオチドを含む調製物を、候補となる作用物質と接触させる工程と、
(b) 前記候補となる作用物質が、前記FAM46Aポリペプチド又はポリヌクレオチドの活性に影響を及ぼすかどうかを検出する工程と、を含む、方法。 - 前記FAM46Aポリペプチド又はポリヌクレオチドを含む前記調製物が、前記FAM46Aポリペプチド又はポリヌクレオチドを含む細胞を含む、請求項8又は9に記載の方法。
- 前記細胞が、脂肪細胞である、請求項10に記載の方法。
- 前記方法が、FAM46Aの発現を低下させる作用物質を同定するためのものである、請求項8〜11のいずれか一項に記載の方法。
- 前記方法が、前記候補となる作用物質が、前記細胞によって産生されたレプチンのレベルに影響を及ぼすかどうかを検出することを更に含む、請求項10又は11に記載の方法。
- 前記候補となる作用物質が天然生成物である、請求項8〜13のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16201666.1 | 2016-12-01 | ||
EP16201666 | 2016-12-01 | ||
PCT/EP2017/080737 WO2018099933A1 (en) | 2016-12-01 | 2017-11-29 | Methods of modulating fam46a |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020510611A JP2020510611A (ja) | 2020-04-09 |
JP2020510611A5 true JP2020510611A5 (ja) | 2021-01-14 |
Family
ID=57539013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019524425A Pending JP2020510611A (ja) | 2016-12-01 | 2017-11-29 | Fam46aを調節する方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20200224195A1 (ja) |
EP (1) | EP3548618A1 (ja) |
JP (1) | JP2020510611A (ja) |
CN (1) | CN109952377A (ja) |
WO (1) | WO2018099933A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111166735B (zh) * | 2020-01-15 | 2023-08-18 | 延边大学 | 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
EP2627349B1 (en) * | 2010-10-15 | 2016-02-03 | The Trustees of Columbia University in the City of New York | Obesity-related genes and their proteins and uses thereof |
US20120094859A1 (en) * | 2010-10-19 | 2012-04-19 | Eva Redei | Methods for detection of depressive disorders |
ES2791627T3 (es) * | 2012-11-12 | 2020-11-05 | Inst Catalana Recerca Estudis Avancats | Métodos y kits para el pronóstico del cáncer colorrectal |
WO2015124588A1 (en) * | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
EP3294418A4 (en) * | 2015-05-08 | 2019-01-02 | President and Fellows of Harvard College | Targeted selection of patients for treatment with cortistatin derivatives |
-
2017
- 2017-11-29 WO PCT/EP2017/080737 patent/WO2018099933A1/en unknown
- 2017-11-29 JP JP2019524425A patent/JP2020510611A/ja active Pending
- 2017-11-29 CN CN201780069627.4A patent/CN109952377A/zh active Pending
- 2017-11-29 US US16/462,706 patent/US20200224195A1/en not_active Abandoned
- 2017-11-29 EP EP17816549.4A patent/EP3548618A1/en not_active Withdrawn
-
2021
- 2021-03-09 US US17/196,592 patent/US20210236593A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boonsanay et al. | Regulation of skeletal muscle stem cell quiescence by Suv4-20h1-dependent facultative heterochromatin formation | |
Luna et al. | Argonaute CLIP defines a deregulated miR-122-bound transcriptome that correlates with patient survival in human liver cancer | |
Roy et al. | Identification of microRNA-124-3p as a putative epigenetic signature of major depressive disorder | |
Yan et al. | Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate ischemic neuronal death by targeting miR-21/PDCD4 signaling pathway | |
Packer et al. | The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease | |
Huang et al. | MicroRNA-374a protects against myocardial ischemia-reperfusion injury in mice by targeting the MAPK6 pathway | |
McDonald et al. | Role of miR-2392 in driving SARS-CoV-2 infection | |
Zovkic et al. | Histone H2A. Z subunit exchange controls consolidation of recent and remote memory | |
Tian et al. | Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p | |
Shibata et al. | The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels | |
Kottemann et al. | Removal of RTF2 from stalled replisomes promotes maintenance of genome integrity | |
Bao et al. | MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-κB pathway during acute viral myocarditis | |
Jarrell et al. | Epigenetics and mechanobiology in heart development and congenital heart disease | |
Chaturvedi et al. | Epigenetic mechanisms underlying cardiac degeneration and regeneration | |
Cui et al. | MicroRNA‐181b and microRNA‐9 mediate arsenic‐induced angiogenesis via NRP1 | |
Diosa-Toro et al. | MicroRNA profiling of human primary macrophages exposed to dengue virus identifies miRNA-3614-5p as antiviral and regulator of ADAR1 expression | |
Schraml et al. | MicroRNAs and toxicology: a love marriage | |
Tao et al. | c-MYC–miRNA circuitry: a central regulator of aggressive B-cell malignancies | |
BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
Biswas et al. | Diabetic retinopathy, lncRNAs, and inflammation: a dynamic, interconnected network | |
JP2019163295A5 (ja) | ||
Wu et al. | LncRNA NEAT1 facilitates the progression of sepsis through up-regulating TSP-1 via sponging miR-370-3p. | |
Bevilacqua et al. | Identification of linc-NeD125, a novel long non coding RNA that hosts miR-125b-1 and negatively controls proliferation of human neuroblastoma cells | |
Gibson | Engineered microRNA therapeutics | |
Metzinger et al. | The management of cardiovascular risk through epigenetic biomarkers |